

PRODUCT INFORMATION



Minocycline (hydrochloride hydrate)

Item No. 14454

Formal Name: (4S,12aS)-4,7-bis(dimethylamino)-1,4,4aS,5,5aR,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacene-carboxamide, monohydrochloride hydrate

Synonym: NSC 141993

MF: C₂₃H₂₇N₃O₇ • HCl [XH₂O]

FW: 493.9


Purity: ≥98%

UV/Vis.: λ_{max}: 257, 342 nm

Supplied as: A crystalline solid

Storage: -20°C

Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Minocycline (hydrochloride hydrate) is supplied as a crystalline solid. A stock solution may be made by dissolving the minocycline (hydrochloride hydrate) in the solvent of choice, which should be purged with an inert gas. Minocycline (hydrochloride hydrate) is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of minocycline (hydrochloride hydrate) in these solvents is approximately 5 and 10 mg/ml, respectively.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of minocycline (hydrochloride hydrate) can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of minocycline (hydrochloride hydrate) in PBS, pH 7.2, is approximately 1 mg/ml. We do not recommend storing the aqueous solution for more than one day.

Description

Minocycline is a broad-spectrum tetracycline antibiotic.¹ It is active against *E. faecium* *in vitro* (MIC = 16 mg/L). Minocycline (20 mg/kg every 12 hours) reduces the number of bacteria in the lung in a mouse model of multidrug resistant *A. baumannii*-induced pneumonia.² It reduces spinal cord lesion size and improves hindlimb function post-injury in a mouse model of acute spinal cord injury when administered at an initial dose of 50 mg/kg and subsequent doses of 25 mg/kg per day for 5 days.³ Formulations containing minocycline have been used in the treatment of acne vulgaris.

References

1. Boukthir, S., Dejoies, L., Zouari, A., *et al.* In vitro activity of eravacycline and mechanisms of resistance in enterococci. *Int. J. Antimicrob. Agents* **56(6)**, 106215 (2020).
2. Ku, N.S., Lee, S.-H., Lim, Y.-S., *et al.* In vivo efficacy of combination of colistin with fosfomycin or minocycline in a mouse model of multidrug-resistant *Acinetobacter baumannii* pneumonia. *Sci. Rep.* **9(1)**, 17127 (2019).
3. Wells, J.E.A., Hurlbert, R.J., Fehlings, M.G., *et al.* Neuroprotection by minocycline facilitates significant recovery from spinal cord injury in mice. *Brain* **126(Pt 7)**, 1628-1637 (2003).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/11/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM